<a href="https://www.fiercebiotech.com/biotech/dd-sees-fibrosis-improvements-mash-resolution-after-rolling-dice-glp-1-drug" hreflang="en">D&D sees fibrosis improvements, MASH resolution after rolling dice on GLP-1 drug</a>
D&D Pharmatech's GLP-1 dual receptor agonist, zabopegdutide, has shown promising results in improving liver fibrosis and resolving metabolic dysfunction-associated steatohepatitis (MASH) in a Phase 2 trial, with significant placebo-adjusted effect sizes. This positions the drug competitively against existing treatments like Novo Nordisk's Wegovy and Madrigal Pharmaceuticals’ Rezdiffra, although the study's small sample size raises questions about the reliability of cross-trial comparisons.
D&D Pharmatech's phase 2 trial results showing statistically significant fibrosis improvement and MASH resolution with zabopegdutide, a GLP-1/glucagon dual receptor agonist, highlight a promising opportunity to penetrate the MASH treatment market, despite competition from established drugs like Novo Nordisk’s Wegovy. For professionals interested in healthtech and biotech investment, this development signals potential growth and innovation in MASH therapies, warranting close monitoring of D&D Pharmatech's progress towards FDA phase 3 trials.